Sonrotoclax monotherapy demonstrates durable efficacy in patients with relapsed/refractory Waldenström macroglobulinemia: 31.5-month follow-up from a phase 1/1b study

ASH 2026 • WM • Sonrotoclax • Poster

Chan Y. Cheah, MBBS (Hons) DMSc FRACP FRCPA

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This phase 1/1b study evaluated investigational sonrotoclax monotherapy across four dose cohorts in patients with relapsed or refractory Waldenström macroglobulinemia (R/R WM). This analysis reported the updated safety and efficacy results with 31.5 months of follow-up. As of May 18, 2026, 23 patients with R/R WM had been enrolled across four dose-escalation cohorts (80 mg, n=6; 160 mg, n=8; 320 mg, n=5; 640 mg, n=4, once daily). Patients had a median of three prior therapies (range, 1-9), with 61% having received a prior Bruton tyrosine kinase (BTK) inhibitor and 96% having received prior anti-CD20 therapy. CXCR4 and TP53 mutations were detected in 41% (n=9/22) and 27% (n=6/22) of tested patients, respectively. The most common any-grade treatment-emergent adverse events (TEAEs; >25%) were COVID-19 (48%), anemia (35%), arthralgia (26%), and diarrhea (26%); anemia was the most common grade ≥3 TEAE (22%). One laboratory tumor lysis syndrome event occurred; no clinical tumor lysis syndrome was reported. No treatment-related deaths were observed. Overall response rate (ORR) was 78%, major response rate (MRR) was 61%, and very good partial response rate was 22%. All patients treated at the 320-mg dose achieved a response (ORR, 100%; MRR, 80%). Responses were also observed among patients previously treated with BTK inhibitors (ORR, 67%) and those with CXCR4 (n=9; ORR, 78%) and TP53 mutations (n=6; ORR, 78%). 

ClinicalTrials.gov ID: NCT04277637

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed